PL1 - Lyophilisate and solvent for solution for injection clinical trials

A Phase 3, Randomized, Double-Blind, Placebo_Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

This study is testing a new medicine, sotatercept, for adults with severe pulmonary arterial hypertension (PAH). Researchers want to see if adding sotatercept to existing treatments can prolong life, prevent lung transplants, or reduce hospital stays related to PAH worsening.